Ofcom\u2019s duties, as the independent regulator for postal services, include furthering the interests of citizens and consumers, where appropriate by promoting competition.<\/p>
<\/p>
Ofcom\u2019s regulatory framework supports competition by imposing minimal intervention in competitive areas of the postal market, for example, in relation to parcel services. Ofcom also requires Royal Mail, as the designated universal service provider, to allow access to its network for the provision of certain bulk letter and large letter services and impose a number of safeguards to protect postal operators reliant on this access.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4931", "label" : {"_value" : "Biography information for Lord Offord of Garvel"} } , "answeringMemberPrinted" : {"_value" : "Lord Offord of Garvel"} , "dateOfAnswer" : {"_value" : "2024-05-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-24T10:02:14.927Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "214"} , "answeringDeptShortName" : {"_value" : "Business and Trade"} , "answeringDeptSortName" : {"_value" : "Business and Trade"} , "date" : {"_value" : "2024-05-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Postal Services: Competition"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what steps they are taking to ensure that the competitive landscape of the UK's postal and parcel delivery market (1) remains fair, and (2) does not lead to monopolistic practices post-takeover.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1796", "label" : {"_value" : "Biography information for Lord Taylor of Warwick"} } , "tablingMemberPrinted" : [{"_value" : "Lord Taylor of Warwick"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/1567852", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1567852/answer", "answerText" : {"_value" : "
Defra funds research directly or by leveraging funding through UK Research & Innovation (UKRI), a BEIS-funded non-governmental public body of which the Biotechnology and Biological Sciences Research Council (BBSRC) is a research council partner. In the last five years, £4.3 million has been invested in research, funded through BBSRC, either solely focussed on avian influenza vaccines, or as part of wider projects for poultry disease control.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1547", "label" : {"_value" : "Biography information for Lord Benyon"} } , "answeringMemberPrinted" : {"_value" : "Lord Benyon"} , "dateOfAnswer" : {"_value" : "2023-01-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-01-24T15:48:05.747Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2023-01-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Avian Influenza: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government, further to the Written Answer by Lord Benyon on 5 December 2022 (HL3620), how much they have invested into research into an avian influenza vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4308", "label" : {"_value" : "Biography information for The Lord Bishop of St Albans"} } , "tablingMemberPrinted" : [{"_value" : "The Lord Bishop of St Albans"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/1386802", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1386802/answer", "answerText" : {"_value" : "
Since its commencement to November 2021, the total spend on Trader Support Service is £204 million.<\/p>
<\/p>
Trader Support Service (TSS) has handled just under 1.4 million Supplementary Declarations since 1 January 2021, with approximately 44,000 traders registered to use the service.<\/p>
<\/p>
Just over 16,800 of our traders are registered in Northern Ireland, with just over 11,500 of those traders actively using the service.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4689", "label" : {"_value" : "Biography information for Lord Agnew of Oulton"} } , "answeringMemberPrinted" : {"_value" : "Lord Agnew of Oulton"} , "dateOfAnswer" : {"_value" : "2021-12-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-12-21T14:29:18.44Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2021-12-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Trader Support Service"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what the total expenditure on the Trader Support Service has been since its commencement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1388", "label" : {"_value" : "Biography information for Lord Dodds of Duncairn"} } , "tablingMemberPrinted" : [{"_value" : "Lord Dodds of Duncairn"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/1197864", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1197864/answer", "answerText" : {"_value" : "
Speaking up is vital for ensuring patient safety and quality services and should be routine business in the National Health Service. As set out in the NHS Freedom to Speak Up policy, anyone in the NHS who wishes to raise a concern can do so through their line management, or lead clinician. If they do not feel comfortable doing so, they can raise concerns through their Freedom to Speak Up Guardian or outside their organisation, for example through the Care Quality Commission. Those seeking guidance on how to raise a concern can call the Speak Up Direct helpline.<\/p>
More broadly, whistle-blowers play an important role in bringing to light wrongdoing in the workplace. The Employment Rights Act 1996, amended by the Public Interest Disclosure Act 1998, gives legal protection to workers who speak up. The legislation is intended to build openness and trust by ensuring that workers who hold their employers to account are treated fairly.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"} } , "answeringMemberPrinted" : {"_value" : "Lord Bethell"} , "dateOfAnswer" : {"_value" : "2020-06-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-06-02T15:46:47.687Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-05-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Disclosure of Information"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what are the protocols in relation to whistle-blowing in the NHS; and what plans they have to issue new guidance to prevent the victimisation of employees in the health and care sectors, including those employed by private companies, who highlight any unsafe, inadequate, inefficient or potentially corrupt practices during the COVID-19 pandemic.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2569", "label" : {"_value" : "Biography information for Lord Greaves"} } , "tablingMemberPrinted" : [{"_value" : "Lord Greaves"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/825296", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/825296/answer", "answerText" : {"_value" : "
Mefloquine is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency, which regulates medication in the UK. Bodies such as the Advisory Committee on Malaria Prevention, the World Health Organization and the United States Centers for Disease Control and Prevention continue to include mefloquine as an option for malaria chemoprophylaxis.<\/p>
<\/p>
The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.<\/p>
<\/p>
For these reasons, there are no plans to add an addendum to the Defence Mental Health and Wellbeing Strategy Report 2017-2022.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"} } , "answeringMemberPrinted" : {"_value" : "Earl Howe"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL4830"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T16:55:22.59Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2018-01-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Armed Forces: Mefloquine"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether the Surgeon General of Her Majesty\u2019s Armed Forces recognises the chronic neurotoxic effects on members of the Armed Forces and Veterans from the administration of mefloquine (Lariam); and whether they will be addressing the problems caused by those effects in the near future.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/675754", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/675754/answer", "answerText" : {"_value" : "
On 23 January 2017, at the Committee stage of the Health Service Medical Supplies (Costs) Bill, I agreed to meet with the noble Lord to discuss clinical pharmacologists and other issues raised about the Bill. I intend to take that opportunity to discuss what further action is required and whether we should speak to other organisations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2017-01-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-01-27T12:09:47.153Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-01-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Clinical Pharmacologists: Training"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether they will convene a meeting between Health Education England, the British Pharmacological Society and the Specialist Advisory Committee for Clinical Pharmacology, which is convened under the auspices of the Royal College of Physicians, to discuss the role and importance of clinical pharmacologists and whether action is needed to prevent a fall in the number of posts and training grades.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"} } , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"} ], "uin" : "HL4829"} , {"_about" : "http://data.parliament.uk/resources/443545", "AnsweringBody" : [{"_value" : "Foreign and Commonwealth Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/443545/answer", "answerText" : {"_value" : "
The British Government has received a number of recent representations on these issues from Parliament and members of the public and is responding in writing.<\/p>
We condemn in the strongest possible terms the atrocities committed by Daesh against all civilians, including Christians, Mandeans, Yazidis, and other minorities, as well as the majority Muslim population who continue to bear the brunt of Daesh\u2019s brutality. The UK has led efforts within the UN to tackle and condemn Daesh and on the protection of civilians more widely. For example, we co-sponsored the UN Human Rights Council Resolution mandating the UN to investigate and report on Daesh abuses.<\/p>
It is a long-standing Government policy that any judgements on whether genocide has occurred are a matter for the international judicial system rather than governments or other non-judicial bodies.<\/p>
Ultimately, the only way to protect Christians, Yazidis and other minorities in the region from Daesh is by defeating this terrible organisation, which in turn requires, amongst other things, ending the conflict in Syria. The Prime Minister, my right hon. Friend the Member for Witney (Mr Cameron), set out the UK\u2019s comprehensive strategy for defeating Daesh and finding a political settlement to the Syria conflict in his response to the Foreign Affairs Committee on 26 November 2015.<\/p>
The joint Office of the United Nations Special Adviser on the Prevention of Genocide and the Special Adviser on the Responsibility to Protect (the Office) are engaged with these issues and publish much of their activity online, including statements in relation to the situation of Christians and other minorities in Syria and Iraq. Our officials maintain regular contact with officials from the Office to discuss issues related to the prevention of genocide and mass atrocities. The Government provides funding for the Office, including for their work with religious leaders and faith based organisations in the Middle East and North Africa region, aimed at the prevention of incitement to violence that could lead to atrocity crimes.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3474", "label" : {"_value" : "Biography information for Baroness Anelay of St Johns"} } , "answeringMemberPrinted" : {"_value" : "Baroness Anelay of St Johns"} , "dateOfAnswer" : {"_value" : "2016-01-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL4827"} , {"_value" : "HL4830"} , {"_value" : "HL4831"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-01-22T13:57:34.343Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "16"} , "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"} , "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"} , "date" : {"_value" : "2016-01-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Islamic State"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether they have any plans to meet the United Nations Special Advisor on the Prevention of Genocide to discuss the situation of Christians and Yazidis in Syria and Iraq.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"} } , "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"} ], "uin" : "HL4829"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 7, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }